Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules

References

• Kontermann RE. Dual targeting strategies with bispecific antibodies. MAbs. 2012;4:182–97. PMID:22453100. doi:10.4161/mabs.4.2.19000.
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20:838–47. PMID:25728220. doi:10.1016/j.drudis.2015.02.008.
   PubMed Web of Science ®Google Scholar
• Zhukovsky EA, Morse RJ, Maus MV. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol. 2016;40:24–35. PMID:26963133. doi:10.1016/j.coi.2016.02.006.
   PubMed Web of Science ®Google Scholar
• Runcie K, Budman DR, John V, Seetharamu N. Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics. Mol Med. 2018;24:50. PMID:30249178. doi:10.1186/s10020-018-0051-4.
   PubMed Web of Science ®Google Scholar
• Dahlén E, Veitonmäki N, Norlén P. Bispecific antibodies in cancer immunotherapy. Ther Adv Vaccines Immunother. 2018;6:3–17. PMID:29998217. doi:10.1177/2515135518763280.
   PubMedGoogle Scholar
• Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the ‘high-hanging fruit‘. Nat Rev Drug Discov. 2018;17:197–223. PMID:29192287. doi:10.1038/nrd.2017.227.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9:182–212. PMID:28071970. doi:10.1080/19420862.2016.1268307.
   PubMed Web of Science ®Google Scholar
• Sedykh SE, Prinz VV, Buneva VN, Nevinsky GA. Bispecific antibodies: design, therapy, perspectives. Drug Des Devel Ther. 2018;12:195–208. PMID:29403265. doi:10.2147/DDDT.S151282.
   PubMed Web of Science ®Google Scholar
• Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67:95–106. PMID:25637431. doi:10.1016/j.molimm.2015.01.003.
   PubMed Web of Science ®Google Scholar
• Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol. 1998;16:677–81. PMID:9661204. doi:10.1038/nbt0798-677.
   PubMed Web of Science ®Google Scholar
• Choi H-J, Kim Y-J, Lee S, Kim Y-S. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity. Mol Cancer Ther. 2013;12:2748–59. PMID:24132142. doi:10.1158/1535-7163.MCT-13-0628.
   PubMed Web of Science ®Google Scholar
• Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo K-M, Huston JS. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel. 2010;23:195–202. PMID:20299542. doi:10.1093/protein/gzp094.
   PubMed Web of Science ®Google Scholar
• de Nardis C, Hendriks LJA, Poirier E, Arvinte T, Gros P, Bakker ABH, de Kruif J. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1. J Biol Chem. 2017;292:14706–17. PMID:28655766. doi:10.1074/jbc.M117.793497.
   PubMed Web of Science ®Google Scholar
• Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, Ng SB, Born T, Retter M, Manchulenko K, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem. 2010;285:19637–46. PMID:20400508. doi:10.1074/jbc.M110.117382.
   PubMed Web of Science ®Google Scholar
• Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A. 2011;108:11187–92. PMID:21690412. doi:10.1073/pnas.1019002108.
   PubMed Web of Science ®Google Scholar
• Wu X, Sereno AJ, Huang F, Zhang K, Batt M, Fitchett JR, He D, Rick HL, Conner EM, Demarest SJ. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies. MAbs. 2015;7:364–76. PMID:25611120. doi:10.1080/19420862.2015.1007826.
   PubMed Web of Science ®Google Scholar
• Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol. 2014;32:191–98. PMID:24463572. doi:10.1038/nbt.2797.
   PubMed Web of Science ®Google Scholar
• Golay J, Choblet S, Iwaszkiewicz J, Cérutti P, Ozil A, Loisel S, Pugnière M, Ubiali G, Zoete V, Michielin O, et al. Design and validation of a novel generic platform for the production of tetravalent IgG1-like bispecific antibodies. J Immunol. 2016;196:3199–211. PMID:26921308. doi:10.4049/jimmunol.1501592.
   PubMed Web of Science ®Google Scholar
• Cooke HA, Arndt J, Quan C, Shapiro RI, Wen D, Foley S, Vecchi MM, Preyer M. EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies. MAbs. 2018;10:1248–59. PMID:30215570. doi:10.1080/19420862.2018.1519631.
   PubMed Web of Science ®Google Scholar
• Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol. 1997;15:159–63. PMID:9035142. doi:10.1038/nbt0297-159.
   PubMed Web of Science ®Google Scholar
• Alt M, Müller R, Kontermann RE. Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Lett. 1999;454:90–94. PMID:10413102.
   PubMed Web of Science ®Google Scholar
• Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu -R-R, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol. 2007;25:1290–97. PMID:17934452. doi:10.1038/nbt1345.
   PubMed Web of Science ®Google Scholar
• Steinmetz A, Vallée F, Beil C, Lange C, Baurin N, Beninga J, Capdevila C, Corvey C, Dupuy A, Ferrari P, et al. CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications. MAbs. 2016;8:867–78. PMID:26984268. doi:10.1080/19420862.2016.1162932.
   PubMed Web of Science ®Google Scholar
• Seifert O, Plappert A, Heidel N, Fellermeier S, Messerschmidt SKE, Richter F, Kontermann RE. The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity. Protein Eng Des Sel. 2012;25:603–12. PMID:22988132. doi:10.1093/protein/gzs059.
   PubMed Web of Science ®Google Scholar
• Seifert O, Plappert A, Fellermeier S, Siegemund M, Pfizenmaier K, Kontermann RE. Tetravalent antibody-scTRAIL fusion proteins with improved properties. Mol Cancer Ther. 2014;13:101–11. PMID:24092811. doi:10.1158/1535-7163.MCT-13-0396.
   PubMed Web of Science ®Google Scholar
• Perisic O, Webb PA, Holliger P, Winter G, Williams RL. Crystal structure of a diabody, a bivalent antibody fragment. Structure. 1994;2:1217–26. PMID:7704531. doi:10.1016/S0969-2126(94)00123-5.
   PubMed Web of Science ®Google Scholar
• Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science. 2001;293:1155–59. PMID:11498595. doi:10.1126/science.1061692.
   PubMed Web of Science ®Google Scholar
• Siegemund M, Pollak N, Seifert O, Wahl K, Hanak K, Vogel A, Nussler AK, Göttsch D, Münkel S, Bantel H, et al. Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. Cell Death Dis. 2012;3:e295. PMID:22495350. doi:10.1038/cddis.2012.29.
   PubMed Web of Science ®Google Scholar
• Schmitt LC, Rau A, Seifert O, Honer J, Hutt M, Schmid S, Zantow J, Hust M, Dübel S, Olayioye MA, et al. Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV. MAbs. 2017;9:831–43. PMID:28421882. doi:10.1080/19420862.2017.1319023.
   PubMed Web of Science ®Google Scholar
• Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong W-J, Sinha R, Guo F, Fabionar H, Wehrman TS, et al. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell. 2015;160:1196–208. PMID:25728669. doi:10.1016/j.cell.2015.02.011.
   PubMed Web of Science ®Google Scholar
• Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer J-P, Liu J, Lim JS, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Invest. 2016;126:2610–20. PMID:27294525. doi:10.1172/JCI81603.
   PubMed Web of Science ®Google Scholar
• Kim JH, Song DH, Youn S-J, Kim JW, Cho G, Kim SC, Lee H, Jin MS, Lee J-O. Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface. Sci Rep. 2016;6:34515. PMID:27682821. doi:10.1038/srep34515.
   PubMed Web of Science ®Google Scholar
• Kwon N-Y, Kim Y, Lee J-O. Structural diversity and flexibility of diabodies. Methods. 2018. PMID:30261312. doi:10.1016/j.ymeth.2018.09.005.
   PubMed Web of Science ®Google Scholar
• Roux KH, Strelets L, Michaelsen TE. Flexibility of human IgG subclasses. J Immunol. 1997;159:3372–82. PMID:9317136.
   PubMed Web of Science ®Google Scholar
• Roux KH, Strelets L, Brekke OH, Sandlie I, Michaelsen TE. Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry. J Immunol. 1998;161:4083–90. PMID:9780179.
   PubMed Web of Science ®Google Scholar
• Digiammarino EL, Harlan JE, Walter KA, Ladror US, Edalji RP, Hutchins CW, Lake MR, Greischar AJ, Liu J, Ghayur T, et al. Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design. MAbs. 2011;3:487–94. PMID:21814039. doi:10.4161/mabs.3.5.16326.
   PubMed Web of Science ®Google Scholar
• Carmichael JA, Power BE, Garrett TPJ, Yazaki PJ, Shively JE, Raubischek AA, Wu AM, Hudson PJ. The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. J Mol Biol. 2003;326:341–51. PMID:12559905. doi:10.1016/S0022-2836(02)01428-6.
   PubMed Web of Science ®Google Scholar
• Wan T, Beavil RL, Fabiane SM, Beavil AJ, Sohi MK, Keown M, Young RJ, Henry AJ, Owens RJ, Gould HJ, et al. The crystal structure of IgE Fc reveals an asymmetrically bent conformation. Nat Immunol. 2002;3:681–86. PMID:12068291. doi:10.1038/ni811.
   PubMed Web of Science ®Google Scholar
• McDonnell JM, Calvert R, Beavil RL, Beavil AJ, Henry AJ, Sutton BJ, Gould HJ, Cowburn D. The structure of the IgE Cepsilon2 domain and its role in stabilizing the complex with its high-affinity receptor FcepsilonRIalpha. Nat Struct Biol. 2001;8:437–41. PMID:11323720. doi:10.1038/87603.
   PubMedGoogle Scholar
• Derrick JP, Wigley DB. Crystal structure of a streptococcal protein G domain bound to an Fab fragment. Nature. 1992;359:752–54. PMID:1436040. doi:10.1038/359752a0.
   PubMed Web of Science ®Google Scholar
• Kato K, Lian LY, Barsukov IL, Derrick JP, Kim H, Tanaka R, Yoshino A, Shiraishi M, Shimada I, Arata Y. Model for the complex between protein G and an antibody Fc fragment in solution. Structure. 1995;3:79–85. PMID:7743134. doi:10.1016/S0969-2126(01)00136-8.
   PubMed Web of Science ®Google Scholar
• Vidal MA, Conde FP. Alternative mechanism of protein A-immunoglobulin interaction the VH-associated reactivity of a monoclonal human IgM. J Immunol. 1985;135:1232–38. PMID:3925002.
   PubMed Web of Science ®Google Scholar
• Sasso EH, Silverman GJ, Mannik M. Human IgM molecules that bind staphylococcal protein A contain VHIII H chains. J Immunol. 1989;142:2778–83. PMID:2495325.
   PubMed Web of Science ®Google Scholar
• Lu D, Jimenez X, Zhang H, Atkins A, Brennan L, Balderes P, Bohlen P, Witte L, Zhu Z. Di-diabody: a novel tetravalent bispecific antibody molecule by design. J Immunol Methods. 2003;279:219–32. PMID:12969563. doi:10.1016/S0022-1759(03)00251-5.
   PubMed Web of Science ®Google Scholar
• Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem. 2005;280:19665–72. PMID:15757893. doi:10.1074/jbc.M500815200.
   PubMed Web of Science ®Google Scholar
• Kipriyanov SM, Moldenhauer G, Braunagel M, Reusch U, Cochlovius B, Le Gall F, Kouprianova OA, von der Lieth CW, Little M. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J Mol Biol. 2003;330:99–111. PMID:12818205. doi:10.1016/S0022-2836(03)00526-6.
   PubMed Web of Science ®Google Scholar
• Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, von der Lieth CW, Matys ER, Little M. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol. 1999;293:41–56. PMID:10512714. doi:10.1006/jmbi.1999.3156.
   PubMed Web of Science ®Google Scholar
• Müller R, Gräwert MA, Kern T, Madl T, Peschek J, Sattler M, Groll M, Buchner J. High-resolution structures of the IgM Fc domains reveal principles of its hexamer formation. Proc Natl Acad Sci U S A. 2013;110:10183–88. PMID:23733956. doi:10.1073/pnas.1300547110.
   PubMed Web of Science ®Google Scholar